144 related articles for article (PubMed ID: 15579031)
21. Genetic basis of cancer of the kidney: disease-specific approaches to therapy.
Linehan WM; Vasselli J; Srinivasan R; Walther MM; Merino M; Choyke P; Vocke C; Schmidt L; Isaacs JS; Glenn G; Toro J; Zbar B; Bottaro D; Neckers L
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6282S-9S. PubMed ID: 15448018
[TBL] [Abstract][Full Text] [Related]
22. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
Kaelin WG
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
[TBL] [Abstract][Full Text] [Related]
23. VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-kappaB-dependent mechanism.
An J; Fisher M; Rettig MB
Oncogene; 2005 Feb; 24(9):1563-70. PubMed ID: 15608669
[TBL] [Abstract][Full Text] [Related]
24. Von Hippel-Lindau disease.
Maher ER
Curr Mol Med; 2004 Dec; 4(8):833-42. PubMed ID: 15579030
[TBL] [Abstract][Full Text] [Related]
25. Association of a novel constitutional translocation t(1q;3q) with familial renal cell carcinoma.
Kanayama H; Lui WO; Takahashi M; Naroda T; Kedra D; Wong FK; Kuroki Y; Nakahori Y; Larsson C; Kagawa S; Teh BT
J Med Genet; 2001 Mar; 38(3):165-70. PubMed ID: 11238683
[TBL] [Abstract][Full Text] [Related]
26. Mutational analysis of the von hippel lindau gene in clear cell renal carcinomas from tuberous sclerosis complex patients.
Duffy K; Al-Saleem T; Karbowniczek M; Ewalt D; Prowse AH; Henske EP
Mod Pathol; 2002 Mar; 15(3):205-10. PubMed ID: 11904337
[TBL] [Abstract][Full Text] [Related]
27. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma.
Foster K; Prowse A; van den Berg A; Fleming S; Hulsbeek MM; Crossey PA; Richards FM; Cairns P; Affara NA; Ferguson-Smith MA
Hum Mol Genet; 1994 Dec; 3(12):2169-73. PubMed ID: 7881415
[TBL] [Abstract][Full Text] [Related]
28. The genetic basis of cancer of the kidney.
Linehan WM; Walther MM; Zbar B
J Urol; 2003 Dec; 170(6 Pt 1):2163-72. PubMed ID: 14634372
[TBL] [Abstract][Full Text] [Related]
29. The genetic locus NRC-1 within chromosome 3p12 mediates tumor suppression in renal cell carcinoma independently of histological type, tumor microenvironment, and VHL mutation.
Lovell M; Lott ST; Wong P; El-Naggar A; Tucker S; Killary AM
Cancer Res; 1999 May; 59(9):2182-9. PubMed ID: 10232606
[TBL] [Abstract][Full Text] [Related]
30. Renal cell carcinoma of end-stage renal disease: a histopathologic and molecular genetic study.
Hughson MD; Schmidt L; Zbar B; Daugherty S; Meloni AM; Silva FG; Sandberg AA
J Am Soc Nephrol; 1996 Nov; 7(11):2461-8. PubMed ID: 8959640
[TBL] [Abstract][Full Text] [Related]
31. Somatic von Hippel-Lindau disease gene mutation in clear-cell renal carcinomas associated with end-stage renal disease/acquired cystic disease of the kidney.
Yoshida M; Yao M; Ishikawa I; Kishida T; Nagashima Y; Kondo K; Nakaigawa N; Hosaka M
Genes Chromosomes Cancer; 2002 Dec; 35(4):359-64. PubMed ID: 12378530
[TBL] [Abstract][Full Text] [Related]
32. Genetic evaluation of von Hippel-Lindau disease for early diagnosis and improved prognosis.
Akcaglar S; Yavascaoglu I; Vuruskan H; Oktay B
Int Urol Nephrol; 2008; 40(3):615-20. PubMed ID: 18074239
[TBL] [Abstract][Full Text] [Related]
33. [Analysis of biallelic inactivation of the von Hippel-Lindau tumor suppressor gene VHL in patients of renal cell carcinoma patient].
Liu N; Gong K; Zhang N; Guo HF; Na X; Wu G; Na YQ
Zhonghua Wai Ke Za Zhi; 2005 Jan; 43(2):115-7. PubMed ID: 15771820
[TBL] [Abstract][Full Text] [Related]
34. Mutations in the von Hippel-Lindau (VHL) gene refine differential diagnostic criteria in renal cell carcinoma.
Barnabas N; Amin MB; Pindolia K; Nanavati R; Amin MB; Worsham MJ
J Surg Oncol; 2002 May; 80(1):52-60. PubMed ID: 11967908
[TBL] [Abstract][Full Text] [Related]
35. Cytogenetic characterization of renal cell carcinoma in von Hippel-Lindau syndrome.
Goodman MD; Goodman BK; Lubin MB; Braunstein G; Rotter JI; Schreck RR
Cancer; 1990 Mar; 65(5):1150-4. PubMed ID: 2302664
[TBL] [Abstract][Full Text] [Related]
36. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
37. Germline and somatic mutations in von Hippel-Lindau disease gene and its significance in the development of kidney cancer.
Shuin T; Kondo K; Ashida S; Okuda H; Yoshida M; Kanno H; Yao M
Contrib Nephrol; 1999; 128():1-10. PubMed ID: 10597373
[No Abstract] [Full Text] [Related]
38. Molecular genetic studies of sporadic and familial renal cell carcinoma.
Gnarra JR; Glenn GM; Latif F; Anglard P; Lerman MI; Zbar B; Linehan WM
Urol Clin North Am; 1993 May; 20(2):207-16. PubMed ID: 8098558
[TBL] [Abstract][Full Text] [Related]
39. Prevalence, morphology and biology of renal cell carcinoma in von Hippel-Lindau disease compared to sporadic renal cell carcinoma.
Neumann HP; Bender BU; Berger DP; Laubenberger J; Schultze-Seemann W; Wetterauer U; Ferstl FJ; Herbst EW; Schwarzkopf G; Hes FJ; Lips CJ; Lamiell JM; Masek O; Riegler P; Mueller B; Glavac D; Brauch H
J Urol; 1998 Oct; 160(4):1248-54. PubMed ID: 9751329
[TBL] [Abstract][Full Text] [Related]
40. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.
Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T
Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
